DE3324563A1 - TUMOR DIAGNOSIS DEVICE - Google Patents

Description

The invention relates to a tumor diagnostic device by means of which, on the basis of the results of Studies of human blood and human plasma carried out by magnetic and optical means can distinguish benign from malignant tumors and in the case of malignant tumors Can diagnose the progression of the disease.

In routine diagnosis, it is very important to distinguish whether a disease is malignant or is benign and, in the event that it is malignant, to recognize the progression of the disease. With malignant Diseases such as B. Carcinosarcoma is for It is essential that clinics make an assessment of the prognosis or a prediction of recovery after surgery. For these purposes, more recently, in addition to conventional procedures such as X-ray examinations

_{B / 13} ORäGINAL INSPECTED

- 4 - DE 3117

and endoscopy, many biochemical and immunological blood analysis methods have been developed. For The determination of a disease is generally based mainly on an overall assessment by the one method mentioned above, but the perfect solution has not yet been achieved.

In recent years, as diagnostic devices, based on analysis of human blood by sorting and measuring blood cells based laser systems have been proposed. Unfortunately, however, it can be stated that the situation has remained the same with regard to tumor diagnosis according to the state of the art.

The invention seeks to make diagnoses using test results that are obtained by the action of a magnetic field in a novel way with the interaction between one Laser beam and human blood. It is the object of the invention to provide a device for diagnosing tumors by combining one on the action of a laser beam on human Blood-based, optical device with the effect

25 to provide a magnetic field.

In the tumor diagnosis device according to the invention, samples of human blood and human Plasma, the patient with various diseases

³ ^ have been taken, irradiated with a visible laser beam, in particular with the argon (Ar) laser beam, the emitted wavelength of which is in the vicinity of 0.5 pm and which is characterized by its sensitivity to human blood and plasma.

³⁵ net.

ORIGINAL INSPECTED

3374563

- 5 - DE 3117

The tumor diagnosis device according to the invention consists a tumor diagnostic system for diagnosing malignant tumors (hereinafter referred to as system A), wherein values of the reflectivity of a sample of human blood or plasma with respect to one Laser beam can be measured with or without application of a magnetic field, whereby malignant tumors are based the change in reflectivity AR resulting from the values measured under both conditions reflectivity obtained, diagnosed, and another tumor diagnostic system for the diagnosis of malignant tumors (hereinafter referred to as system B), wherein the angle of scattering of the laser beam in samples of human plasma under the conditions that a magnetic field is applied and that no magnetic field is applied, can be measured, with malignant tumors based on the change of the scattering angle ΔΘ, which was obtained from the angles measured under both conditions, diagnosed

Turn 20.

The system A in turn consists of an optical device for the irradiation of blood samples, the People with various diseases were removed with a visible laser beam, e.g. B. an Ar laser beam with a wavelength in the vicinity of 0.5 pm, and for achieving the reflected Beam and from a magnetic device which has a direct current magnetic field which is necessary for the

^ow distinguishing the malignancy of diseases from their benignity results in required change in the reflected beam. The system B is arranged so that it the scattering angle of the laser beam, which under the conditions that the magnetic field is applied and that no magnetic field is applied, through the

ORIGINAL INSPECTED

- 6 - DE 3117

Samples of human plasma passed through, measure and then based on the change in Scattering angle, which is due to the presence of the magnetic field, can diagnose tumors.

For a more detailed explanation, reference is made to FIGS. 1 to 20 and Tables 1 to 3.

Figure 1 is a basic schematic for system A.10

Fig. 2 is an experimental scheme for system A, ″ and

Fig. 3 explains its main part. 15 Fig. 4 is a basic scheme for system B.

Fig. 5 is an experimental scheme for system B.

Figures 6 through 20 are graphical representations showing results obtained using the apparatus of the present invention explain the measured changes in the reflection capacity or the scattering angle.

Table 1 shows correlations between various human blood cell characteristics and the change of reflectivity AR.

Table 2 shows correlations between various characteristics of human plasma and the change

of reflectivity AR.

Table 3 shows measured values obtained by statistical analysis

of correlations between different parameters

of human plasma and the change of the scattered ^p winkeis ΔΘ obtained.

ORIGINAL INSPECTED

- 7 - DE 3117

First, a blood sample 2 is dropped onto a glass plate 1_ as shown in FIG. 1. The refractive indices of the air 0, the glass plate _1_ and the sample 2 are as n _n , n, and n _o (as more complex

"- UX cL

Index) given. If the light intensity E. is below the angle of incidence Θ. is incident on the sample 2, which has been applied to the glass plate I ^, the light intensity E reflected by the sample 2 is expressed as follows, insofar as the light reflected from the first surface of the glass plate is neglected:

^E out ⁼ 4 ^r 2 ^E in ' ⁽¹⁾

where t- is the transmittance of the glass plate ¹ ^ ^ L and r_ is the reflectance of the sample 2 .

Human blood is generally made up of two main components: plasma and blood cells. Generally more than 97 % of the plasma content is ionized, and about 10 % of the blood cell content is also ionized. As a result, these ionized particles must predominate in terms of optical properties when a magnetic field is applied. Further, "these optical refractive indexes can have a large

Have wavelength dependence, which is due to the properties of the ions, molecules and atoms contained is conditional.

If there is no magnetic field, the refraction 30

index the blood sample to an isotropic form, which is determined by

n ₂ = n ₂ - ik, (2)

J Z 4 O b J

DE 3117

is given, where n_ and k denote the real and the imaginary, respectively Mean refractive index. When a magnetic field is applied to the sample, the refractive index takes the form of an anisotropic tensor with each component η in the following manner. . get because all charged and ionized particles are influenced by the magnetic field (cf. K. G. Budden, Radio Wave in the Ionosphere, Cambridge Univ. Press, London, 1961, page 199):

xx '

xy 'xz

yy 'yz

ⁿ zx ' ⁿ zy' ⁿ zz

(3)

When the amplitude reflectivity of the blood sample
(of the plasma or blood cells) under and without application of a magnetic field is r ₂ (H) or r ₂ (0), the change in the reflected light intensity ΔΕ, which is due to the application of the magnetic field, is
expressed as follows:

ΔΕ

out

in ^[r 2 < ^H > - ^r 2 ^(0)]

(4)

When this expression is expressed by the reflected light intensity / d obtained without applying the magnetic field. H. ,

= tf ^ r ₂ (0) E is _{normalized in} 7, the normalized change in the light intensity Ar is expressed as follows:

Ar =

- r ₂ (0)

r ₂ (0)

Cr ₂ (H) -

^E in

(5)

ORIGINAL INSPECTED

- 9 - DE 3117

I 12 Since the intensity reflectivity R as R = IrI is defined, the normalized change in reflectivity AR is given by the following expression:

AR = [R ₂ (H) - R ₂ (O)] / R ₂ (O), (6)

where R _? (H) and Rp (O) mean the reflectivity with and without application of a magnetic field.

Because between malignant and benign diseases there are small differences in the nature and the Particle shape of the blood of the blood cell or plasma sample should consist of its reflectivity can be changed by applying a magnetic field. As a result, it may be possible to be much more accurate to distinguish whether the disease is malignant or benign by looking at the value of the blood cell and AR of the plasma component is determined, the characteristics of the AR distribution are explored and statistical correlations are found searches between AR and various parameters of common blood samples.

In fact, experiments based on such considerations and using the inventive System A, desired results as described below were obtained will.

³ ® An Ar ion laser 1_1 (NEC 3201) which can be tuned with a Littrow prism was used as the light source, which is shown in FIG. 2.

Since it had been observed in preliminary tests that the changes in reflectivity both in the case of plasma

- 10 - DE 3117

as well as for blood cells at the wavelength of 0.5017 μΐη selected from eight possible wavelengths tend to differ greatly depending on whether the disease is malignant or benign To distinguish, this wavelength was used in all experiments.

The normally polarized beam, ie the electric field component perpendicular to the plane of incidence, was incident on the glass plate JL4 at an angle of incidence θ of 45, the beam having passed through the attenuator 1_2 and being reflected by the mirror M. The intensity of the beam which reached the blood sample JL3 located on the glass plate 14 was adjusted to a few mW by the attenuator 12 in order to prevent damage to the sample. Each sample was dropped in approximately the same amount with a pipette onto the glass plate 14 , which was about 5 mm thick. The glass plate JL4 was cleaned after each measurement using a hemolytic, enzymatic solvent (Amkoa 300).

A direct current magnetic field IJi of about 2.5 kOe was applied ² ^ perpendicular to the plane of incidence to measure the change in reflectance due to the magnetic field. Only the beam reflected by the sample Ij3 was filtered out by the iris diaphragm Ij> arranged immediately after the mirror M "(see FIG. 3), received by the measuring sensor JUS and measured and recorded by the recording device Y] _. (That is, other reflected rays not reflected from the sample were not admitted into the probe 1J3 as shown in Fig. 3.)

ORIGINAL INSPECTED

- 11 - DE 3117

The following description relates to the system B illustrated in FIGS. 4 and 5.

Human plasma has a high transmission capacity for the entire range of visible light. When visible light with a certain wavelength hits plasma that is in a test cell, incident, the light is however through particles present as constituents of the plasma with a certain Scattering angle scattered. In addition, the scattering angle shows a certain change when a magnetic field is applied to the plasma is applied because the plasma to which a magnetic field is applied, predominantly by electrically charged Particles such as B. ion is occupied.

On the basis of such considerations, in the inventive system B, a sample 22_ of human plasma was dropped onto the glass plate 21_ , and the sample was applied in the direction of that shown in FIG

A magnetic field is applied to the arrow. The values of the incident intensity of the laser beam from the interface 23 , ie the second reflecting surface, between the sample £ 2_ and the glass plate 2 ^ L were

under the conditions that the magnetic field is applied 25

and that no magnetic field was applied, was determined and defined as I (H) and 1 (0), respectively. By normalizing the change in intensity ΔΙ due to the application of the magnetic field on the basis of

1 (0) became the change in reflectivity AR 30th

as follows from the reflectivity R (H) under application of the magnetic field and the reflectivity R (O) calculated without applying the magnetic field:

35 ^{ΔΚ =} CR (H) - R (O)] / R (O). (7)

· ■■ · ■ ··

- 12 - DE 3117

On the other hand, as already mentioned, in the case that a beam with a certain wavelength is incident on human plasma, the transmitted beam is scattered, and then the angle of scatter varies similar to the case of the reflectivity depending on whether the magnetic field is applied or not, and the change in the scattering angle ΔΘ is therefore given by the following expression:

10 · ΔΘ = [Θ (Η) - θ (Ο)] / θ (Ο), (8)

where Θ (Η) and θ (0) mean the scattering angle of the beam in the entire half-width with application and without application of the magnetic field.
15th

The tests were carried out using an apparatus as illustrated in FIG.

An Ar ion laser 3 ^ (NEC 3201) tunable with a Littrow prism was used as the light source, and the wavelength was set to 0.5017 pm . The normally polarized beam, ie the electric field component perpendicular to the plane of incidence, "from the laser ^ L was incident on the glass plate 34 at an angle of incidence of 45 °, the beam being passed through an attenuator (not shown) and a beam splitter 32 .. had passed through and reflected by mirror 3 ^ 3. The intensity of the beam which reached sample 35,

30 -

was set to a few mW by the attenuator to prevent damage to the sample. Each sample 35 was applied in approximately the same amount with a pipette to the glass plate 34 which is approximately 5 mm thick

was, dripped on. Several dozen glass plates 35

were used for a number of measurements and

replaced each time in turn.

ORIGINAL INSPECTED

- 13 - DE 3117

A direct current magnetic field is applied to the sample 35_ by the magnetic field application device 3 € s 36 ' parallel to the plane of incidence and perpendicular to the beam direction. The beam reflected by the interface between the sample 35_ and the glass plate 34 is reflected by the mirror _37, filtered out by the iris diaphragm _38_, enlarged by the lens _39, received by the sensor 40 (GSD-100) and by a recording device (not shown ) measured, recorded and calculated.

With regard to the main characteristics of the system B according to the invention, reference is made to the lower part of FIG. An Ar ion laser beam with a wavelength of, for example, 0.5017 / µm is split by the beam splitter ^ 2 and reflected by the mirror _41 and falls on the plasma cell 42! a. On the other hand, a direct current magnetic field is applied to the cell by the magnetic field applying means 43-, 43 ' , which is arranged opposite the cell £ 2 and perpendicular to the incident beam. The transmitted laser beam is enlarged by the lenses 44, and its scattering angle is determined by the InAs light sensor £ 5 having a small opening. The measuring sensor £ 5 is arranged on an automatic apparatus table (not shown). The entire half width of the determined angle is measured and recorded by a recording device (not shown). In this example

SO became a direct current magnetic field by the magnetic field applying means of 3.0 kOe applied.

For testing using system A, patients with a malignant or benign disease and also healthy adults with corresponding

- 14 - DE 3117

blood samples taken during medical treatment and separated into plasma and blood cells. Fig. 6 is a two-dimensional representation of the changes of the reflectivity AR for both components, with the ordinate and the abscissa on refer to the constituent plasma or blood cells. Malignant diseases, benign diseases and malignant Illnesses after surgery will be with

denoted by the symbols ▲, ο and δ.

As a result, the symbols of all the samples are found to be in the third quadrant, but the samples from patients with malignant diseases and the samples from patients with benign diseases tend to be different from each other; Samples α from patients with malignant diseases are comparatively close to the coordinate origin with a smaller AR value, while samples ο from patients with benign diseases are comparatively far removed from the coordinate origin and show a larger AR value. In addition, many samples δ taken from patients with malignant diseases after an operation tend to be far from the origin of coordinates. Samples from healthy people tend to cluster in the area where the two main situations overlap, that is, the critical area. In addition, a radius I Rl

less than 0.485 with a significance number of 30th

10 % some cautionary information in the sense that there is a numerical possibility of malignant disease being present.

Furthermore, FIGS. 7 to 13 show the correlation between AR and various characteristic values in conventional blood samples. When these correlations using a digital

ORIGINAL INSPECTED

- 15 - DE 3117

Computer to determine the average index, the covariance, the regression line and the correlation coefficient Statistically analyzed, blood cells and plasma were those in table

5 1 and Table 2, respectively, were obtained.

Table 1, which relates to blood cells, shows the mean concentration of corpuscular Hemoglobin (MCHC) has a high correlation, while the number of red blood cells (RBC), the amount of hemoglobin (Hb) and the hematocrit value (Hct) have some correlation demonstrate. The number of platelets (plat.), The number of white blood cells (WBC), the mean blood cell volume (MCV) and the mean amount of

! 5 corpuscular hemoglobin (MCH) show no correlation.

In Table 2 relating to plasma, iron (Fe), albumin; * ι ~ »β- ^and / -globulin and the jaundice index each have a high correlation, while sodium (Na), potassium (K), total protein, the albumin / globulin ratio (A / G) and c & _? -Globulin each show some correlation. Chlorine (Cl) and total cholesterol

rin show no correlation. 25th

Since these correlations depend to a large extent on Whether the diseases are malignant or benign, they should be very effective means of distinguishing between represent malignant and benign diseases.

For the test using system B, the relationships between both the change in the scattering angle in plasma (ΔΘ) and the change in reflectivity of plasma (AR) as well as between ΔΘ and Characteristic values examined in plasma samples, in particular with regard to the combined group of samples,

"* - * 16 - DE 3117

the patients with benign diseases and patients with böijart lifted tumors after an operation and regarding the group of specimens from patients with malignant tumors.

Fig. 14 is a two-dimensional illustration showing refers to ΔΘ as a function of AR for plasma samples. In Fig. 14 (and also in Figs. 15 to 20) benign diseases, malignant tumors and Malignant tumors after an operation are designated with the symbol ο, α or δ. According to the findings of Fig. 14 is for the group of specimens, the patients with benign diseases and patients with malignant Diseases taken after surgery were found to have a low correlation between AR and ΔΘ (r = 0.11; P = 0.5), while for the group of samples from patients with malignant tumors a negative Correlation is found (r = -0.28; P = 0.2).

FIGS. 15 to 20 show correlations between ΔΘ and characteristics of blood samples, and only in relation to cases in which a comparatively significant Correlation was found. Fig. 15 shows the correlation between ΔΘ and Fe, and Figs. 16 to 20 show in turn the correlation between ΔΘ and Na, albumin, o ^ '-globulin, ^ -globulin and total bilirubin. Tabel 3 shows the results of the statistical analysis of correlations between ΔΘ and various characteristic values.

In summary it can be stated that regarding the group of samples, the patients with benign Illnesses and patients with malignant diseases after surgery were taken, correlations between ΔΘ and characteristic values including the Fe,

35 Na and albumin values' can be found and that too with regard to the group of samples from patients with malignant tumors, correlations between ΔΘ and characteristic

ORJGJNAL INSPECTED

- 17 - DE 3117

values including the α.-, Cb _? - and y-globulin values and the total bilirubin are found. These findings indicate that the diagnosis of malignant tumors may be possible based on the change in the angle of scattering of a selected plasma-transmitted laser beam with the application of a magnetic field.

Tabel

Correlations between different core values and the change reflectivity (blood cells)

IU
b
t Average R (%) Covari number Regression line constant Correlation j RBC m
b
t index -0.694
-1.264
-0.970 -4, 145
10, 587
-1, 037 Steiguno (10 "^) -0, 227
-2, 203
-0.870 coefficient Man m
b
t 409.24
439.24
424.24 -0.683
-1.260
-0.971 -0, 110
0, 304
-0, 023 -0, 114
0.218
-0, 024 -0, 125
-2, 079
-0.894 -0, 130
0, 106
-0, 014 Hct m
b
t 12.655
13,461
13, 058 -0.692
-0.966
-0.825 -0, 370
0 * 665
-0, 012 -4, 407
6, 089
-0.594 -0, 148
-1 640
-0.811 -0, 133
0.095
-0.011 WBC m
b
t 38.939
41, 097
39, 984 -0, 709
-0.959
-0.830 -88,577
-66 ^ 269
-67, 066 -1, 397
1, 640
-0, 034 -0 611
-1 056
-θ | 746 -0, 137
0, 1 89
-0.004 plat. m
b
t 6796.9
7640.0
7204.8 -0.674
-0, 966
-0.816 -0.199
0.291
-0.155 -0.0014
0, 0013
-0, 0012 -0.585
-1.251
-0.723 -0.068
0.051
-0.050 MCV m
b
t 14, 609
17, 210
15, 869 -0.691
-1 043
-0.892 0.103
-1.325
-0.234 -0, 606
1.656
-0.584 -0.816
-0.641
-0.466 -0.069
0, 124
-0.055 MCH m
b
t 95, 724
91, 141
95, 126 -0.692
-0, 962
-0.825 0 103
0 000
0 ^ 078 0.131
-0.448
-0.441 -1, 034
-0.959
-1, 190 0.022
-0.109
-0.048 MCHC 31, 14 2
30, 778
30, 919 -0.692
-1,043
-0.865 . 0.074
0.157
0.114 1.097
-0.009
1.180 -3.926
-7.925
-5.919 0.064
0.000
0.054 3-2, 533
32, 523
32, 5 29 9,942
21, 160
15,540 0.163
0.260
0.209

(Note) m: malignant, b: benign, t: overall

Reflectivity. (Plasma)

O)

m
b
t Average R [%) Covariance Regression line constant Correlation
coefficient Fe m
b
t index -0.74 2
-1, 148
-0.948 7.465
-0.418
4,542 Slope (1 (T ² ) -1.072
-1, 121
-1.158 +0.442
-0.023
0. 230 N / A m
b
t 92, 357
81, 207
86, 584 -0, 784
-1, 142
-0, 966 -0.249
-0.034
-0.197 0.357
-0.033
0.272 3, 553
-1.768
2,454 -0.193
0.026
-0.139 K m
b
t 135, 4 8
136, 61
136, 06 -0, 788
-1, 142
-0. 974 -0.035
0.013
-0, 010 -3, 200
0.458
-2, 513 0, 107
-1, 449
-0.736 -0.193
0.065
-0 048 Cl m
b
t 3, 967
4.018
3.986 -0, 812
-1, 142
-0 988 -0.144
-0, 128
-0, 137 -22, 570
7, 630
-5, 960 0.804
0.186
0.501 -0.107
-θ'θ84
-0,091 Total-
protein m
b
t 99.655
99.818
99,774 -0, 762
-1, 142
-0.961 -0.059
0.030
-0.053 -1, 622
-1, 331
-1, 4 9 3 -0.362
-1, 548
-0.697 -0.136
0.086
-0, _091 A / G m
b
t 6.623
6.861
6 652 -0.771
-1.137
-0.955 -0, 019
-0.008
-0, 035 -6, 046
5, 913
-3, 9 8 2 -0.429
-0.995
-0 ι405 -0.159
-0.059
-0 .239 albumin m
b
t 1.256
1.468
1, 366 -0, 762
-1.142
-0.961 -0, 070
-0.005
-0.083 -27, 250
-9, 675
-40, 290 -0, 148
-1,049
-0, 077 -0 248
-0, 021
-0 274 ⁰ V
Globe. m
b
t 3,615
4.107
3.873 -0.762
-1.113
-0.946 -0.001
0.027
0 .015 -17, 020
-2, 276
-2JL 850 -0, 722
-1, 721
-1, 347 -0, 023
0.385
0.232 ^a 2-
Globe. m
b
t 0.4173
0.4124
0, 4162 -0.762
-1.142
-0.961 -0, 011
0.017
-0 .002 -9, 665
147, 390
96, 300 -0, 637
-1, 393
-0.941 -0, 106
0, 160
-0, 014 ß-
Globe. m
b
t 0, 6403
0.6933
0 ^ 6 681 -0.754
-1, 140
-0.957 -0, 028
-0.005
-0, 015 -19, 510
36 _} 180
-3,031 -0, 151
-0.933
-0, 513 -0.343
-0, 078
-0, 193 Y-
Globe. m
b
t 0.6963
0.6936
0.6949 -0.762
-1.172
-0.961 0.055
-0.002
0, 050 -86 540
-29 850
-63,980 -1, 072
-1, 156
-1, 261 0, 27 0
-0, 012
0, 235 Total-
Cholesterii m
b
t 1, 1967
0, 9603
1 .0606 -0.808
-1, 142
-0.983 0.878
-0, 096
1. 153 25,850
-1.628
28.240 -0.908
-1, 133
-1. 108 0, 050
-0.005
0.059 Jaundice
index 176.1 "/
166 82
171.27 -0.765
-1, 135
-0.973 0.584
-0.085
0.305 0.057
-0.006
0.073 -1, 137
-1.059
-1, 197 0.387
-0, 071
0. 21 1 6, 208
5.097
5,582 6,000
-1, 497
4,000

«Oca ο α β

CjO CO ro

cn cn co

(Note) m: malignant, b: benign, t: overall

Table 3. ΔΘ-AR properties of plasma

a
b Average ΔΘ (%) Covariance Regression line constant Correlation
coefficient P. Fe a
b index -0, 076
0, 158 13, 443
14, 816 Slope (KT ² ) -1.205
-1.173 0.219
0.307 0.7
0.3 N / A a
b 80, 7 5
56, 53 0.413
-0.294 0.509
1, 490 0.014
0.024 -10, 52
-26.00 0.086
0.253 0.9
0, 2 albumin a
b 140, 60
140, 13 -0.069
-0.333 -0, 185
0.251 0.078
0, 184 2.355
-3,343 -0, 112
0, 207 0.7
0.3 α, -Globulin a
b 4, 254
4, 073 0.580
-0.174 -0, 014
-0, 064 -0, 570
0.739 1, 243
1, 803 -0.087
-0, 364 0, 8
0.1 (^ -Globulin a
b 0.232
0.264 0.580
-0.177 0, 035
-0, 079 -2, 853
-7, 502 -0.297
1,300 0, 100
-0, 234 0, 8
0, 3 ß-globulin a
b 0.572
0.587 0.580
-0.177 0.058
0, 021 1, 533
-2,515 -1,048
-1, 135 0.155
0, 091 0.7
0.7 γ-globulin a
b 0.727
0.674 0.580
-0.177 -0.030
-0 _s 112 2 241
1, 4 22 0.947
1, 118 -0, 044
-0, 208 0, 9
0, 4 Total-
Bilirubin 1, 066
0.928 0 412
O ', 351 0.051
-0.249 -0, 34 4
-1, 396 0.353
0.810 0, 025
-0, 309 0, 9
0.1 0 914
0.697 0, 065
-1, 667

(Note) a: malignant, b: benign and malignant after surgery

Claims (3)

Claims l. Tumor diagnosis device, characterized in that that malignant tumors on the basis of various values that indicate the properties of a blood or blood View plasma sample and under the conditions of irradiation with a visible laser beam and measured without applying a direct current magnetic field to the sample. 2.J tumor diagnosis device according to claim 1, characterized in that it consists of a tumor diagnosis system A. for diagnosis of malignant tumors, which in turn consists of a glass plate, on the surface of which every blood or plasma sample is applied and a visible laser beam incident on its back from the back the sample reflects, a sensor for the determination of the reflected beam, a recording device for the measurement and recording of the determined value and a magnetic field application device for applying a direct current magnetic field B / 13 - 2 - DE 3117 to the sample, which reduces the reflectance values of the sample with respect to the laser beam or can be determined without applying a magnetic field and which can be used for diagnosing malignant tumors Changes in reflectivity are determined, and another tumor diagnosis system B ₁ for the diagnosis of malignant tumors, which in turn consists of a plasma cell permeable to the visible laser beam, a magnetic field application device for applying a direct current magnetic field to the plasma sample located in the cell, a sensor for determining the scattering angle of the beam which has been transmitted through the plasma in the cell, and a recording device for measuring and recording the entire half-width on the basis of the above-mentioned determined values, whereby changes in the scattering angle of the beam under and useful for the diagnosis of malignant tumors can be determined without applying a magnetic field, consists. 25th 3. Tumor diagnostic device according to claim 1, characterized in that the visible laser beam is an argon laser beam. ORIGINAL INSPECTED